Former Teva Pharmaceutical Industries senior executive Yafit Stark has joined the scientific advisory committee of Tel Aviv-listed medical cannabis company Cannassure Therapeutics Ltd. Stark established Teva’s Global Clinical Research Department under its Innovative R&D Division, and was responsible for the company’s clinical development program during the development of Teva’s multiple sclerosis drug Copaxone.
Stark’s knowledge and experience will help Cannassure establish itself as a leader in research and development, Cannassure’s chairman Ido Nehoshtan said in a statement.
Read more at calcalistech.com
